Innovent Biologics (IVBXF) announced that China’s National Medical Products Administration has approved a New Drug Application of Dovbleron, a ...

today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, ...

Eli Lilly and Co. (LLY) said that the National Medical Products Administration (NMPA) in China has approved Kisunla (donanemab-azbt, ...

(“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, ...

President-elect Donald Trump has been staffing his next administration since ... Bhattacharya as the director of the National Institutes of Health, the medical research agency.

The approval marks the first indication of MSD’s KEYTRUDA in the earlier stages of NSCLC in China. Credit: JHVEPhoto/Shutterstock. China National Medical Products Administration (NMPA) has approved ...